Opinion
Video
Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.